Korro Bio
- Sector
- Biotech
- Headquarters
- CAMBRIDGE, MA
- Founded
- 2018
- Latest Form D
- $4M, Jun 2019
- Total capital
- $4M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $4M
- 1 Form D · last Jun 2019
- 89 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 7
- 33 pending · first 2022
- Rank in peer group#213 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$4M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#213 · top 15%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Jean-Francois FormelaDirectorNamed in SEC Form D filings
- Nessan BerminghamExecutive Officer, Director, PromoterNamed in SEC Form D filings
- Ommer ChohanExecutive Officer, Director, PromoterNamed in SEC Form D filings
What it has protected
USPTO · 7 granted of 40- PendingMethods and Compositions for the Adar-Mediated Editing of Argininosuccinate Synthetase (ASS1)USPTOApplication 19381941
- PendingMethods and Compositions for the Adar-Mediated Editing of Argininosuccinate Lyase (ASL)USPTOApplication 19377927
- GrantedRna-editing Oligonucleotides And Uses ThereofUSPTOUS 12,668,801
Show all 40 patent records
- Methods and Compositions for the Adar-Mediated Editing of Argininosuccinate Synthetase (ASS1)Jul 16, 2026 · Application 19381941Pending
- Methods and Compositions for the Adar-Mediated Editing of Argininosuccinate Lyase (ASL)Jul 2, 2026 · Application 19377927Pending
- Rna-editing Oligonucleotides And Uses ThereofJun 30, 2026 · US 12,668,801Granted
- Methods and Compositions for the ADAR-Mediated Editing of ABCA4Jun 18, 2026 · Application 19366161Pending
- Rna-editing Oligonucleotides And Uses ThereofJun 11, 2026 · Application 19051812Pending
- GalNAc conjugated oligonucleotides for RNA editingMar 12, 2026 · Application 19329194Pending
- Methods and Compositions for Adar-Mediated EditingDec 25, 2025 · Application 19189150Pending
- Rna-editing Oligonucleotides And Uses ThereofDec 18, 2025 · Application 19296642Pending
- Methods And Compositions For Disrupting NRF2-KEAP1 Protein Interaction By Adar Mediated Rna EditingNov 20, 2025 · Application 18700152Pending
- RNA-Editing Oligonucleotides and Uses ThereofOct 21, 2025 · US 12,448,620Granted
- Rna-editing Oligonucleotides And Uses ThereofJul 3, 2025 · Application 18927268Pending
- Rna-editing Oligonucleotides And Uses ThereofFeb 27, 2025 · Application 18941793Pending
- Methods and Compositions for ADAR-Mediated EditingJan 30, 2025 · Application 18570918Pending
- Methods and Compositions for ADAR-Mediated EditingJan 30, 2025 · Application 18570938Pending
- RNA-Editing Oligonucleotides and Uses ThereofDec 24, 2024 · US 12,173,285Granted
- RNA-Editing Oligonucleotides and Uses ThereofNov 26, 2024 · US 12,152,050Granted
- Methods and Compositions for Adar-Mediated EditingAug 8, 2024 · Application 18290062Pending
- RNA-Editing Oligonucleotides and Uses ThereofJul 9, 2024 · US 12,031,131Granted
- Methods And Compositions For The Adar-mediated Editing Of Argininosuccinate Lyase (asl)Sep 21, 2023 · Application 17986023Pending
- Methods And Compositions For The Adar-mediated Editing Of Leucine Rich Repeat Kinase 2 (LRRK2)Sep 21, 2023 · Application 17986014Pending
- Methods And Compositions For The Adar-mediated Editing Of Transmembrane Channel-like Protein 1 (TMC1)Aug 31, 2023 · Application 17985974Pending
- Methods And Compositions For The Adar-mediated Editing Of Retinochisin 1 (RS1)Aug 31, 2023 · Application 17985978Pending
- Methods And Compositions For The Adar-mediated Editing Of Methyl-cpg Binding Protein 2 (MECP2)Aug 31, 2023 · Application 17985970Pending
- Methods And Compositions For The Adar-mediated Editing Of Gap Junction Protein Beta 2 (GJB2)Aug 31, 2023 · Application 17985963Pending
- Methods And Compositions For The Adar-mediated Editing Of Argininosuccinate Synthetase (ASS1)Aug 17, 2023 · Application 17986017Pending
- Methods And Compositions For The Adar-mediated Editing Of Otoferlin (otof)Jul 6, 2023 · Application 17986020Pending
- Methods and Compositions for the ADAR-Mediated Editing of ABCA4Jun 8, 2023 · Application 17924063Pending
- Rna-editing Oligonucleotides And Uses ThereofOct 25, 2022 · US 11,479,575Granted
- RNA-Editing Enzyme-Recruiting Oligonucleotides and Uses ThereofSep 29, 2022 · Application 17702978Pending
- Rna-editing Oligonucleotides And Uses ThereofSep 27, 2022 · US 11,453,878Granted
- Methods and Compositions for the ADAR-Mediated Editing of SERPINA1Dec 9, 2021 · Application 17332400Pending
- Rna-editing Oligonucleotides And Uses ThereofDec 10, 2020 · Application 16749608Pending
- Rna-editing Oligonucleotides And Uses ThereofApplication 19493944Pending
- Double-stranded Rna-editing Oligonucleotides And Uses ThereofApplication PCTUS2024059734Pending
- Stabilized Mutant Glul Proteins And Uses ThereofApplication PCTUS2025060544Pending
- Methods And Compositions For The Adar-mediated Editing Of Adenosine Monophosphate (amp)-activated Protein Kinase (ampk)Application 63969733Pending
- Rna-editing Oligonucleotides And Uses ThereofApplication 63734854Pending
- Galnac Conjugated Oligonucleotides For Rna EditingApplication PCTUS2025043523Pending
- Methods And Compositions For The Adar-mediated Editing Of Adenosine Monophosphate (amp)-activated Protein Kinase (ampk)Application PCTUS2026015609Pending
- Xk Nucleobases In Adar Editing OligosApplication PCTUS2026017921Pending
Related companies, and why
- Intellia TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Judo BioSimilar federal contract value in Biotech · null in contracts
- Kinaset TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Altis LabsSimilar federal contract value in Biotech · null in contracts
- Matchpoint TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Obsidian TherapeuticsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .